Boston Scientific Corporation (NYSE:BSX) has tumbled 2.3% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 0.54% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.13%. Boston Scientific Corporation (NYSE:BSX) has underperformed the index by 0.38% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Boston Scientific Corporation (NYSE:BSX): The stock opened at $22.87 on Friday but the bulls could not build on the opening and the stock topped out at $22.91 for the day. The stock traded down to $22.32 during the day, due to lack of any buying support eventually closed down at $22.49 with a loss of -1.49% for the day. The stock had closed at $22.83 on the previous day. The total traded volume was 40,495,410 shares.
The company shares have rallied 26.07% from its 1 Year high price. On Jun 9, 2016, the shares registered one year high at $23.35 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $22.44 and the 200 Day Moving Average price is recorded at $19.26.
On the companys insider trading activities, The officer (EVP, GC & Chief Admin Officer), of Boston Scientific Corp, Pratt Timothy A. had unloaded 24,229 shares at $22.66 per share in a transaction on June 1, 2016. The total value of transaction was $549,029. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. Guggenheim Securities initiates coverage on Boston Scientific Corporation (NYSE:BSX). The rating major has initiated the coverage with buy rating on the shares. The rating by the firm was issued on June 9, 2016. Currently the company Insiders own 1.31% of Boston Scientific Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.95% . Institutional Investors own 93.31% of Boston Scientific Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -21.18%.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.